AE. Posch, Ares Genetics GmbH, Vienna, Austria
Antibiotic resistance is a major public health burden increasingly resulting in fatal patient outcomes. The continued rise in antibiotic resistance is projected to claim more than 10 million casualties/year by 2050 and a concomitant reduction of 2% to 3.5% in the gross domestic product globally. Here we introduce the Genetic Antibiotic Resistance and Susceptibility Database (GEAR), the most comprehensive collection of pathogen genomes and antibiotic resistance profiles, developed in a translational research partnership with the Chair for Clinical Bioinformatics at Saarland University. GEAR contains the entire DNA sequences of more than 11,000 bacterial strains as well as related sensitivity data for 21 antibiotics. The strains were isolated from patient samples at over 200 sites across the world over the last three decades.
GEAR allows to assemble and annotate bacterial genomes from next-generation sequencing raw data, identify genetic variations in those genomes and correlate them with the response of the respective bacterial strain to antibiotics. This talk will illustrate how GEAR can be used to advance our understanding about the genetic foundations of antibiotic resistance, monitor and investigate global patterns of emerging antibiotic resistance as well as enable personalized and optimized treatment based on next-generation infectious disease diagnostics.
Andreas E. Posch is Managing Director of Ares Genetics GmbH, a wholly owned subsidiary of Curetis GmbH, a developer of next-level molecular diagnostic solutions. Ares Genetics develops, advances and commercializes novel approaches to improve the rapid detection of antibiotic resistance in patients with microbial infections as well as tools to accelerate antibiotic research.
Andreas Posch has joined Ares Genetics from Siemens, where he was responsible for Bioinformatics Strategy and Innovation at Siemens Healthcare. As designated Principal Key Expert for Bioinformatics & Systems Medicine, he designed, executed and directed global innovation and R&D projects focusing on next-generation sequencing for diagnostic purposes, biomarker discovery, multi-scale disease modeling, advanced clinical decision support as well as genetic antibiotic resistance testing (GEAR). He holds a PhD from the "Applied Bioscience Technology" program at the Vienna University of Technology.